FAQs

Yes, the 2026 program is designed for teams moving from preclinical proof-of-concept into regulatory engagement, initial trial planning, and early-phase clinical execution. Sessions focus on clinical data generation, dosing strategies, and FDA expectations for in vivo modalities.

Clinical leaders will share case studies covering trial design, patient selection, dose escalation, immunogenicity management, and the translation of NHP data to humans. These sessions help senior teams benchmark their clinical strategy against peers.

Experts will discuss targeted LNP engineering, protein-based delivery, vector pseudo typing and advanced non-human primate models that improve specificity and reduce off target effects. These insights help R&D leaders refine their delivery platforms.

Yes, the agenda includes balanced scientific debate across LNP systems, mRNA-based payloads, AAV, lentiviral vectors, VLPs and other emerging platforms.

Senior decision makers can compare durability, payload capacity, safety trends and regulatory perceptions.

A dedicated Spotlight on Asia examines accelerated clinical timelines, IIT opportunities, emerging CDMO capacity and clinical data produced by Chinese biotechs. This enables BD and strategy leaders to assess when and how to leverage the APAC ecosystem.

Yes. Companies from both early and advanced pipelines will present clinical and translational data spanning in vivo CAR T, in vivo T cell programming, gene editing payloads and multi tissue targeting. This provides meaningful comparison points for competitive analysis.

You will hear directly from clinical leaders who have already taken in vivo candidates through pre‑IND and IND meetings. They will explain what the FDA focused on in their own interactions, including biodistribution, safety monitoring, CMC readiness, and trial design. This gives senior leaders practical guidance based on real experience that they can apply immediately.

The pharma search and evaluation panel discussion will provide insight into what drives valuations, how pharma evaluates in vivo platforms and which delivery technologies are attracting the most capital. This helps leaders position their programs for partnerships.

Yes, the sessions will clearly outline where ex vivo and in vivo development diverge, including differences in CMC expectations, regulatory risk, delivery challenges, and clinical study design. Leaders who have already built in vivo programs explain how they adapted their workflows, teams, and decision frameworks when shifting from ex vivo foundations. This provides R&D and strategy teams with a practical roadmap for evaluating if, and how they can expand into in vivo modalities.

Speakers will discuss NHP model selection, toxicology signals, biodistribution mapping, and translational workflows that support more predictive movement into the clinic. These insights are particularly relevant for scientific and translational leaders.

Attendees include Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, R&D Vice Presidents, Translational Heads, and Business Development executives from top in vivo companies, along with global pharma innovation leads.

The intimate format provides for high-quality one-to-one interactions, filled with candid conversations.

Data driven sessions explore immune activation patterns, repeat dosing considerations, durability enhancements and strategies to minimize toxicity in in vivo settings. These discussions support better design of long-term therapeutic profiles.

Leading developers will share next-generation systems that improve targeting, editing precision, and payload stability. This is especially relevant for platforms evaluating future delivery upgrades.

You can register directly through the “Register” section on the website (ensure you review the pricing & registration details). Alternatively, contact us at info@hansonwade.com and a member of our team will be in touch shortly.

Group discounts of up to 20% are available when you attend with 4 or more colleagues. Attend with a colleague for a 10% discount.

View full registration details here.

For enquiries regarding registration, speaking opportunities or press, please contact info@hansonwade.com. For sponsorship enquiries, please contact sponsor@hansonwade.com.

Or view our Contact Us page.